You are right to point out the benefit to come of the R&D tax credit of $4.8m. I doubt it will be enough to turn them cash positive this quarter because the full effects of cost reductions dont come through until Q1 14. Still, it's a big help which the doom and gloom merchants have ignored.
You also highlight the potential for positive newsflow on multiple fronts on the product portfolio. Again, completely ignored by the critics.
Fairly confident we have passed the turning point.
PXS Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
